Home›Global Markets›North America›Biotech IPOs surge as US market lags, returning 55% on…

Biotech IPOs surge as US market lags, returning 55% on average in 2026

Biotech offerings this year have far outperformed the broader US IPO market, which is down 4.4% on a weighted-average basis excluding blank-check companies.

Reported · Written up by our desk · North America

Biotech and pharmaceutical initial public offerings are outperforming the wider US IPO market, supported by a strong start to 2026 that has attracted more capital into the healthcare sector, according to data compiled by Bloomberg and covered by LiveMint Markets.

Weighted average returns for US biotech and pharma IPOs have reached 55% this year, versus a weighted average 4.4% loss for the broader US IPO market, excluding blank-check companies and other financial vehicles, Bloomberg data show.

At least six biotechs, led by CRISPR-based genetic medicines developer Scribe Therapeutics Inc., have filed for IPOs this month, with potential pricing later in July and the first half of August before seasonal IPO activity pauses.

The advance comes as the Nasdaq Biotechnology Index is up 13% this year, with investors citing a more stable regulatory backdrop, trial data breakthroughs, and recent big pharma acquisitions, including AbbVie’s purchase of Apogee Therapeutics, GSK’s deal for Nuvalent, and Vertex’s purchase of Crinetics Pharmaceuticals, LiveMint Markets said.

Latest closeNasdaq Comp. 25,881.95 ▼1.5%

More like this

Sources